(NASDAQ: EQ) Equillium's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.55%.
Equillium's earnings in 2026 is -$18,009,000.On average, 12 Wall Street analysts forecast EQ's earnings for 2026 to be -$15,236,962, with the lowest EQ earnings forecast at -$19,263,375, and the highest EQ earnings forecast at -$11,984,127. On average, 12 Wall Street analysts forecast EQ's earnings for 2027 to be -$16,473,420, with the lowest EQ earnings forecast at -$26,720,166, and the highest EQ earnings forecast at -$9,986,773.
In 2028, EQ is forecast to generate -$19,593,097 in earnings, with the lowest earnings forecast at -$27,341,565 and the highest earnings forecast at -$14,647,267.